vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $57.2M, roughly 1.0× Vanda Pharmaceuticals Inc.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -246.8%, a 163.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 7.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 9.8%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
RYTM vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $57.2M |
| Net Profit | $-47.5M | $-141.2M |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | -70.5% |
| Net Margin | -83.0% | -246.8% |
| Revenue YoY | 36.9% | 7.6% |
| Net Profit YoY | -9.6% | -2774.3% |
| EPS (diluted) | $-0.73 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $57.2M | ||
| Q3 25 | $51.3M | $56.3M | ||
| Q2 25 | $48.5M | $52.6M | ||
| Q1 25 | $32.7M | $50.0M | ||
| Q4 24 | $41.8M | $53.2M | ||
| Q3 24 | $33.3M | $47.7M | ||
| Q2 24 | $29.1M | $50.5M | ||
| Q1 24 | $26.0M | $47.5M |
| Q4 25 | $-47.5M | $-141.2M | ||
| Q3 25 | $-52.9M | $-22.6M | ||
| Q2 25 | $-46.6M | $-27.2M | ||
| Q1 25 | $-49.5M | $-29.5M | ||
| Q4 24 | $-43.3M | $-4.9M | ||
| Q3 24 | $-43.6M | $-5.3M | ||
| Q2 24 | $-32.3M | $-4.5M | ||
| Q1 24 | $-141.4M | $-4.1M |
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 88.6% | — | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | -70.5% | ||
| Q3 25 | -102.6% | -55.6% | ||
| Q2 25 | -93.4% | -73.2% | ||
| Q1 25 | -143.7% | -82.0% | ||
| Q4 24 | -98.6% | -19.3% | ||
| Q3 24 | -132.0% | -23.1% | ||
| Q2 24 | -139.2% | -20.1% | ||
| Q1 24 | -538.7% | -19.5% |
| Q4 25 | -83.0% | -246.8% | ||
| Q3 25 | -103.1% | -40.1% | ||
| Q2 25 | -96.1% | -51.7% | ||
| Q1 25 | -151.4% | -58.9% | ||
| Q4 24 | -103.6% | -9.2% | ||
| Q3 24 | -131.2% | -11.2% | ||
| Q2 24 | -110.9% | -9.0% | ||
| Q1 24 | -544.4% | -8.7% |
| Q4 25 | $-0.73 | $-2.40 | ||
| Q3 25 | $-0.82 | $-0.38 | ||
| Q2 25 | $-0.75 | $-0.46 | ||
| Q1 25 | $-0.81 | $-0.50 | ||
| Q4 24 | $-0.71 | $-0.09 | ||
| Q3 24 | $-0.73 | $-0.09 | ||
| Q2 24 | $-0.55 | $-0.08 | ||
| Q1 24 | $-2.35 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $327.2M |
| Total Assets | $480.2M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $84.9M | ||
| Q3 25 | $416.1M | $70.0M | ||
| Q2 25 | $291.0M | $81.0M | ||
| Q1 25 | $314.5M | $111.8M | ||
| Q4 24 | $320.6M | $102.3M | ||
| Q3 24 | $298.4M | $100.5M | ||
| Q2 24 | $319.1M | $103.0M | ||
| Q1 24 | $201.2M | $125.2M |
| Q4 25 | $139.1M | $327.2M | ||
| Q3 25 | $148.8M | $466.0M | ||
| Q2 25 | $-11.9M | $486.3M | ||
| Q1 25 | $18.9M | $511.4M | ||
| Q4 24 | $21.7M | $538.5M | ||
| Q3 24 | $11.2M | $541.2M | ||
| Q2 24 | $39.3M | $542.5M | ||
| Q1 24 | $61.6M | $544.0M |
| Q4 25 | $480.2M | $488.9M | ||
| Q3 25 | $506.9M | $601.1M | ||
| Q2 25 | $372.7M | $624.7M | ||
| Q1 25 | $386.7M | $631.9M | ||
| Q4 24 | $392.3M | $656.2M | ||
| Q3 24 | $363.6M | $645.1M | ||
| Q2 24 | $381.8M | $651.4M | ||
| Q1 24 | $258.7M | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $-29.4M | ||
| Q3 25 | $-26.6M | $-31.6M | ||
| Q2 25 | $-23.3M | $-15.3M | ||
| Q1 25 | $-40.4M | $-33.1M | ||
| Q4 24 | $-18.8M | $-1.8M | ||
| Q3 24 | $-25.2M | $-14.6M | ||
| Q2 24 | $-29.1M | $-6.9M | ||
| Q1 24 | $-40.7M | $7.6M |
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | — | $-14.7M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
